Neurochemical Research

, Volume 35, Issue 8, pp 1259–1268 | Cite as

Effects of Iron Chelators, Iron Salts, and Iron Oxide Nanoparticles on the Proliferation and the Iron Content of Oligodendroglial OLN-93 Cells

  • Michaela Hohnholt
  • Mark Geppert
  • Ralf Dringen
Original Paper


The oligodendroglial cell line OLN-93 was used as model system to investigate the consequences of iron deprivation or iron excess on cell proliferation. Presence of ferric or ferrous iron chelators inhibited the proliferation of OLN-93 cells in a time and concentration dependent manner, while the application of a molar excess of ferric ammonium citrate (FAC) prevented the inhibition of proliferation by the chelator deferoxamine. Proliferation of OLN-93 cells was not affected by incubation with 300 μM iron that was applied in the form of FAC, FeCl2, ferrous ammonium sulfate or iron oxide nanoparticles, although the cells efficiently accumulated iron during exposure to each of these iron sources. The highest specific iron content was observed for cells that were exposed to the nanoparticles. These data demonstrate that the proliferation of OLN-93 cells depends strongly on the availability of iron and that these cells efficiently accumulate iron from various extracellular iron sources.


Oligodendrocytes Iron Proliferation Deferoxamine Iron oxide nanoparticles 



Michaela Hohnholt and Mark Geppert are members of the Ph.D. graduate school nanoToxCom at the University of Bremen. Michaela Hohnholt is financially supported by a grant from the University Bremen (BFK) and Mark Geppert is a recipient of a Ph.D. fellowship from the Hans-Böckler Stiftung. We like to thank Prof. C. Richter-Landsberg (Oldenburg, Germany) for kindly providing us with OLN-93 cells and Maike Schmidt for her help with the microscopy.


  1. 1.
    Galaris D, Skiada V, Barbouti A (2008) Redox signaling and cancer: the role of “labile” iron. Cancer Lett 266:21–29CrossRefPubMedGoogle Scholar
  2. 2.
    Kruszewski M (2003) Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531:81–92PubMedGoogle Scholar
  3. 3.
    Dringen R, Bishop GM, Koeppe M et al (2007) The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res 32:1884–1890CrossRefPubMedGoogle Scholar
  4. 4.
    Brodie C, Siriwardana G, Lucas J et al (1993) Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res 53:3968–3975PubMedGoogle Scholar
  5. 5.
    Lederman HM, Cohen A, Lee JW et al (1984) Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 64:748–753PubMedGoogle Scholar
  6. 6.
    Green DA, Antholine WE, Wong SJ et al (2001) Inhibition of malignant cell growth by 311, a novel iron chelator of the pyridoxal isonicotinoyl hydrazone class: effect on the R2 subunit of ribonucleotide reductase. Clin Cancer Res 7:3574–3579PubMedGoogle Scholar
  7. 7.
    Cooper CE, Lynagh GR, Hoyes KP et al (1996) The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J Biol Chem. 271:20291–20299CrossRefPubMedGoogle Scholar
  8. 8.
    Thelander L, Graslund A, Thelander M (1983) Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem Biophys Res Commun 110:859–865CrossRefPubMedGoogle Scholar
  9. 9.
    Nyholm S, Mann GJ, Johansson AG et al (1993) Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J Biol Chem. 268:26200–26205PubMedGoogle Scholar
  10. 10.
    Dayani PN, Bishop MC, Black K et al (2004) Desferoxamine (DFO)-mediated iron chelation: rationale for a novel approach to therapy for brain cancer. J Neurooncol 67:367–377CrossRefPubMedGoogle Scholar
  11. 11.
    Richardson DR (1997) Potential of iron chelators as effective antiproliferative agents. Can J Physiol Pharmacol 75:1164–1180CrossRefPubMedGoogle Scholar
  12. 12.
    Yu Y, Kovacevic Z, Richardson DR (2007) Tuning cell cycle regulation with an iron key. Cell Cycle. 6:1982–1994PubMedGoogle Scholar
  13. 13.
    Connor JR, Menzies SL (1996) Relationship of iron to oligodendrocytes and myelination. Glia. 17:83–93CrossRefPubMedGoogle Scholar
  14. 14.
    Benkovic SA, Connor JR (1993) Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J Comp Neurol 338:97–113CrossRefPubMedGoogle Scholar
  15. 15.
    Garrick MD, Garrick LM (2009) Cellular iron transport. Biochim Biophys Acta 1790:309–325PubMedGoogle Scholar
  16. 16.
    Hulet SW, Menzies S, Connor JR (2002) Ferritin binding in the developing mouse brain follows a pattern similar to myelination and is unaffected by the jimpy mutation. Dev Neurosci 24:208–213CrossRefPubMedGoogle Scholar
  17. 17.
    Todorich B, Pasquini JM, Garcia CI et al (2009) Oligodendrocytes and myelination: the role of iron. Glia. 57:467–478CrossRefPubMedGoogle Scholar
  18. 18.
    Song N, Jiang H, Wang J et al (2007) Divalent metal transporter 1 up-regulation is involved in the 6-hydroxydopamine-induced ferrous iron influx. J Neurosci Res 35:3118–3126CrossRefGoogle Scholar
  19. 19.
    Burdo JR, Menzies SL, Simpson IA et al (2001) Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. J Neurosci Res 66:1198–1207CrossRefPubMedGoogle Scholar
  20. 20.
    Todorich B, Zhang X, Slagle-Webb B et al (2008) Tim-2 is the receptor for H-ferritin on oligodendrocytes. J Neurochem 107:1495–1505CrossRefPubMedGoogle Scholar
  21. 21.
    Hulet SW, Hess EJ, Debinski W et al (1999) Characterization and distribution of ferritin binding sites in the adult mouse brain. J Neurochem 72:868–874CrossRefPubMedGoogle Scholar
  22. 22.
    Richter-Landsberg C, Heinrich M (1996) OLN-93: a new permanent oligodendroglia cell line derived from primary rat brain glial cultures. J Neurosci Res 45:161–173CrossRefPubMedGoogle Scholar
  23. 23.
    Geppert M, Hohnholt M, Gaetjen L et al (2009) Accumulation of iron oxide nanoparticles by cultured brain astrocytes. J Biomed Nanotechnol. 5:285–293CrossRefPubMedGoogle Scholar
  24. 24.
    Riemer J, Hoepken HH, Czerwinska H et al (2004) Colorimetric ferrozine-based assay for the quantitation of iron in cultured cells. Anal Biochem 331:370–375CrossRefPubMedGoogle Scholar
  25. 25.
    Bishop GM, Robinson SR (2001) Quantitative analysis of cell death and ferritin expression in response to cortical iron: implications for hypoxia-ischemia and stroke. Brain Res 907:175–187CrossRefPubMedGoogle Scholar
  26. 26.
    Moos T, Mollgard K (1993) A sensitive post-DAB enhancement technique for demonstration of iron in the central nervous system. Histochemistry. 99:471–475PubMedGoogle Scholar
  27. 27.
    Dringen R, Kussmaul L, Hamprecht B (1998) Detoxification of exogenous hydrogen peroxide and organic hydroperoxides by cultured astroglial cells assessed by microtiter plate assay. Brain Res Brain Res Protoc. 2:223–228CrossRefPubMedGoogle Scholar
  28. 28.
    Schmidt MM, Dringen R (2009) Differential effects of iodoacetamide and iodoacetate on glycolysis and glutathione metabolism of cultured astrocytes. Front Neuroenergetics. 1:1–10PubMedGoogle Scholar
  29. 29.
    Lowry OH, Rosebrough NJ, Farr AL et al (1951) Protein measurement with the Folin phenol reagent. J Biol Chem. 193:265–275PubMedGoogle Scholar
  30. 30.
    Hoepken HH, Korten T, Robinson SR et al (2004) Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. J Neurochem 88:1194–1202CrossRefPubMedGoogle Scholar
  31. 31.
    Gharagozloo M, Khoshdel Z, Amirghofran Z (2008) The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine. Eur J Pharmacol 589:1–7CrossRefPubMedGoogle Scholar
  32. 32.
    Keberle H (1964) The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 119:758–768CrossRefPubMedGoogle Scholar
  33. 33.
    Richardson DR, Baker E (1994) Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake. J Cell Physiol 161:160–168CrossRefPubMedGoogle Scholar
  34. 34.
    Ware JL, Paulson DF, Webb KS (1984) 1, 10-Phenanthroline reversibility inhibits proliferation of two human prostate carcinoma cell lines (PC-3 and DU145). Biochem Biophys Res Commun 124:538–543CrossRefPubMedGoogle Scholar
  35. 35.
    Szuts D, Krude T (2004) Cell cycle arrest at the initiation step of human chromosomal DNA replication causes DNA damage. J Cell Sci 117:4897–4908CrossRefPubMedGoogle Scholar
  36. 36.
    Trinder D, Morgan E (1998) Mechanisms of ferric citrate uptake by human hepatoma cells. Am J Physiol 275:G279–G286PubMedGoogle Scholar
  37. 37.
    Zhu L, Glahn RP, Yeung CK et al (2006) Iron uptake by Caco-2 cells from NaFeEDTA and FeSO4: Effects of ascorbic acid, pH, and a Fe(II) chelating agent. J Agric Food Chem 54:7924–7928CrossRefPubMedGoogle Scholar
  38. 38.
    Liddell JR, Hoepken HH, Crack PJ et al (2006) Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity. J Neurosci Res 84:578–586CrossRefPubMedGoogle Scholar
  39. 39.
    Brand A, Schonfeld E, Isharel I et al (2008) Docosahexaenoic acid-dependent iron accumulation in oligodendroglia cells protects from hydrogen peroxide-induced damage. J Neurochem 105:1325–1335CrossRefPubMedGoogle Scholar
  40. 40.
    Schroder I, Johnson E, de Vries S (2003) Microbial ferric iron reductases. FEMS Microbiol Rev 27:427–447CrossRefPubMedGoogle Scholar
  41. 41.
    Tulpule K, Robinson SR, Bishop GM et al (2010) Uptake of ferrous iron by cultured rat astrocytes. J Neurosci Res 88:563–571PubMedGoogle Scholar
  42. 42.
    Attieh ZK, Mukhopadhyay CK, Seshadri V et al (1999) Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem. 274:1116–1123CrossRefPubMedGoogle Scholar
  43. 43.
    Conrad ME, Umbreit JN, Moore EG et al (2000) Separate pathways for cellular uptake of ferric and ferrous iron. Am J Physiol Gastrointest Liver Physiol. 279:G767–G774PubMedGoogle Scholar
  44. 44.
    Schonberg DL, McTigue DM (2009) Iron is essential for oligodendrocyte genesis following intraspinal macrophage activation. Exp Neurol 218:64–74CrossRefPubMedGoogle Scholar
  45. 45.
    Islam T, Josephson L (2009) Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark. 5:99–107PubMedGoogle Scholar
  46. 46.
    Ge Y, Zhang Y, Xia J et al (2009) Effect of surface charge and agglomerate degree of magnetic iron oxide nanoparticles on KB cellular uptake in vitro. Colloids Surf B Biointerfaces. 73:294–301CrossRefPubMedGoogle Scholar
  47. 47.
    Weinstein JS, Varallyay CG, Dosa E et al (2010) Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab 30:15–35CrossRefPubMedGoogle Scholar
  48. 48.
    Xie J, Wang J, Niu G et al (2010) Human serum albumin coated iron oxide nanoparticles for efficient cell labeling. Chem Commun (Camb). 46:433–435CrossRefGoogle Scholar
  49. 49.
    Pisanic TR 2nd, Blackwell JD, Shubayev VI et al (2007) Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 28:2572–2581CrossRefPubMedGoogle Scholar
  50. 50.
    Dunning MD, Lakatos A, Loizou L et al (2004) Superparamagnetic iron oxide-labeled Schwann cells and olfactory ensheathing cells can be traced in vivo by magnetic resonance imaging and retain functional properties after transplantation into the CNS. J Neurosci 24:9799–9810CrossRefPubMedGoogle Scholar
  51. 51.
    Falangola MF, Lee SP, Nixon RA et al (2005) Histological co-localization of iron in Abeta plaques of PS/APP transgenic mice. Neurochem Res 30:201–205CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Michaela Hohnholt
    • 1
    • 2
  • Mark Geppert
    • 1
    • 2
  • Ralf Dringen
    • 1
    • 2
    • 3
  1. 1.Center for Biomolecular Interactions BremenUniversity of BremenBremenGermany
  2. 2.Center for Environmental Research and Sustainable TechnologyUniversity of BremenBremenGermany
  3. 3.School of Psychology and PsychiatryMonash UniversityClaytonAustralia

Personalised recommendations